News

11/19/09, Xarelto Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE more

11/11/09, Company Healthcare: Fight against Neglected Diseases As part of its societal responsibilities, Bayer HealthCare puts special emphasis on therapies for the so-called neglected diseases. More than 3.3 billion people, half of the world’s population,... more